Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2009 1
2010 1
2011 2
2012 2
2013 1
2014 1
2016 2
2017 2
2018 5
2019 1
2020 1
2021 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.
Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S. Toy W, et al. Nat Genet. 2013 Dec;45(12):1439-45. doi: 10.1038/ng.2822. Epub 2013 Nov 3. Nat Genet. 2013. PMID: 24185512 Free PMC article.
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.
Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, Hsieh W, Sanchez-Vega F, Brown DN, Da Cruz Paula AF, Morris L, Selenica P, Eichenberger E, Shen R, Schultz N, Rosen N, Scaltriti M, Brogi E, Baselga J, Reis-Filho JS, Chandarlapaty S. Li Z, et al. Among authors: toy w. Cancer Cell. 2018 Dec 10;34(6):893-905.e8. doi: 10.1016/j.ccell.2018.11.006. Cancer Cell. 2018. PMID: 30537512 Free PMC article.
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.
Toy W, Weir H, Razavi P, Lawson M, Goeppert AU, Mazzola AM, Smith A, Wilson J, Morrow C, Wong WL, De Stanchina E, Carlson KE, Martin TS, Uddin S, Li Z, Fanning S, Katzenellenbogen JA, Greene G, Baselga J, Chandarlapaty S. Toy W, et al. Cancer Discov. 2017 Mar;7(3):277-287. doi: 10.1158/2159-8290.CD-15-1523. Epub 2016 Dec 16. Cancer Discov. 2017. PMID: 27986707 Free PMC article.
ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer.
Kingston B, Pearson A, Herrera-Abreu MT, Sim LX, Cutts RJ, Shah H, Moretti L, Kilburn LS, Johnson H, Macpherson IR, Ring A, Bliss JM, Hou Y, Toy W, Katzenellenbogen JA, Chandarlapaty S, Turner NC. Kingston B, et al. Among authors: toy w. Cancer Discov. 2024 Feb 8;14(2):274-289. doi: 10.1158/2159-8290.CD-22-1387. Cancer Discov. 2024. PMID: 37982575 Free PMC article.
Somatic estrogen receptor α mutations that induce dimerization promote receptor activity and breast cancer proliferation.
Irani S, Tan W, Li Q, Toy W, Jones C, Gadiya M, Marra A, Katzenellenbogen JA, Carlson KE, Katzenellenbogen BS, Karimi M, Segu Rajappachetty R, Del Priore IS, Reis-Filho JS, Shen Y, Chandarlapaty S. Irani S, et al. Among authors: toy w. J Clin Invest. 2024 Jan 2;134(1):e163242. doi: 10.1172/JCI163242. J Clin Invest. 2024. PMID: 37883178 Free PMC article.
Novel breast cancer metastasis-associated proteins.
Ho J, Kong JW, Choong LY, Loh MC, Toy W, Chong PK, Wong CH, Wong CY, Shah N, Lim YP. Ho J, et al. Among authors: toy w. J Proteome Res. 2009 Feb;8(2):583-94. doi: 10.1021/pr8007368. J Proteome Res. 2009. PMID: 19086899
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors.
Razavi P, Dickler MN, Shah PD, Toy W, Brown DN, Won HH, Li BT, Shen R, Vasan N, Modi S, Jhaveri K, Caravella BA, Patil S, Selenica P, Zamora S, Cowan AM, Comen E, Singh A, Covey A, Berger MF, Hudis CA, Norton L, Nagy RJ, Odegaard JI, Lanman RB, Solit DB, Robson ME, Lacouture ME, Brogi E, Reis-Filho JS, Moynahan ME, Scaltriti M, Chandarlapaty S. Razavi P, et al. Among authors: toy w. Nat Cancer. 2020 Apr;1(4):382-393. doi: 10.1038/s43018-020-0047-1. Epub 2020 Mar 23. Nat Cancer. 2020. PMID: 32864625 Free PMC article.
The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells.
Fanning SW, Jeselsohn R, Dharmarajan V, Mayne CG, Karimi M, Buchwalter G, Houtman R, Toy W, Fowler CE, Han R, Lainé M, Carlson KE, Martin TA, Nowak J, Nwachukwu JC, Hosfield DJ, Chandarlapaty S, Tajkhorshid E, Nettles KW, Griffin PR, Shen Y, Katzenellenbogen JA, Brown M, Greene GL. Fanning SW, et al. Among authors: toy w. Elife. 2018 Nov 29;7:e37161. doi: 10.7554/eLife.37161. Elife. 2018. PMID: 30489256 Free PMC article.
Defining the Energetic Basis for a Conformational Switch Mediating Ligand-Independent Activation of Mutant Estrogen Receptors in Breast Cancer.
Mayne CG, Toy W, Carlson KE, Bhatt T, Fanning SW, Greene GL, Katzenellenbogen BS, Chandarlapaty S, Katzenellenbogen JA, Tajkhorshid E. Mayne CG, et al. Among authors: toy w. Mol Cancer Res. 2021 Sep;19(9):1559-1570. doi: 10.1158/1541-7786.MCR-20-1017. Epub 2021 May 21. Mol Cancer Res. 2021. PMID: 34021071 Free PMC article.
23 results